Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session

Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death

About This Webinar

Sponsored by Eurofins DiscoverX

During the development of antibody therapeutics, regulators now require assays to evaluate Fc effector function demonstrating immune cell-mediated killing via ADCC and ADCP rather than a surrogate endpoint for antibody engagement of antigen on target cells. Eurofins DiscoverX’s KILR® cytotoxicity assay platform specifically measures antibody-mediated killing of antigen-expressing target cells in co-culture with effector cells. This platform is now available as ready-to-use bioassays for several tumor models, including Raji and Daudi, for use in screening and lot-release applications. These bioassays are qualified with Rituximab and demonstrate high repeatability and inter-analyst performance.

Abzena, an integrated early discovery to mid-phase biotherapeutics development services provider, independently evaluated KILR Raji Bioassay cells in both ADCC and ADCP assays to offer clients a robust platform for ranking and characterization studies.

In this webinar, we demonstrate that these bioassay cells show excellent reproducibility in ADCC assays with both KILR CD16 Effector Cells and PBMCs. We will show that the bioassay cells provide a quantitative readout for ADCP, with a large assay window and high signal-to-background ratios.

Learning Objectives:

  • Learn about new ready-to-use bioassays for measuring direct cell death in antibody dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cell phagocytosis (ADCP) assays

  • Find out more about minimizing variability in ADCC for screening applications

  • Discover how robust and reproducible assays are used in lot release programs

Who can view: Everyone
Webinar Price: Free
Featured Presenters
Webinar hosting presenter
Director, Bioassays, Abzena
Dr. Erika Kovacs is the Director of Bioassays at Abzena where she currently leads the Bioassay team to support drug discovery and development efforts with cell-based assays for lead selection, characterization, potency, and safety. Erika has extensive experience in designing and developing custom assays for unique mode of actions and is the lead in championing technology development efforts to extend Abzena’s portfolio and launch new offerings.

Erika has over 15 years of experience in developing cell-based and biochemical assays to study various aspects of cancer and immune cell function. Most recently, as a postdoctoral candidate at the University of California, Berkeley, Erika studied structure-function relationships in the EGFR-Ras-MAPK cancer signaling pathway and the TCR-Ras-MAPK immune signaling pathway. At Abzena, Erika has been responsible for developing the Fc functional assay package to assess the ADCC and ADCP triggering activity of biologics and delivered a wide range of custom assay development projects. Her expertise lies in designing functional assays for potency assessment and mechanism of action studies.

Erika has an extensive background in studying cancer and immune signaling pathways. Proficient in assay development, optimization and data analysis using a wide range of techniques, such as flow cytometry, fluorescence and luminescence plate-based assays and fluorescence microscopy.
Webinar hosting presenter
Director, R&D Department, Eurofins DiscoverX
Dr. Jane Lamerdin is the Director of R&D at Eurofins DiscoverX where she currently oversees the development of novel cell-based assays and tools to support portfolio expansion as well as client-focused projects. She has nearly 20 years of industry experience developing and prosecuting diverse cell-based assays to support client drug discovery campaigns, and high throughput, molecular and systems biology research. Prior to joining Eurofins DiscoverX, Jane was Executive Director of Research at Odyssey Thera, where she utilized her expertise in cell signaling pathways, oncology and DNA repair to guide the development of a broad panel of high content cell-based assays for compound safety and selectivity screening. This development supported programs in major pharma companies as well as the ToxCast program at the EPA. Jane received her B.S. and Ph.D. in Genetics from the University of California at Davis; she is co-inventor on over 5 patents and has co-authored over 50 peer-reviewed articles.
Attended (67)